Merit Medical to Acquire Needle Biopsy Products in Purchase Agreement With BD

 

November 21, 2017—Merit Medical Systems, Inc. announced that it has signed an asset purchase agreement to acquire with BD’s (Becton, Dickinson and Company) soft tissue core needle biopsy products, which include the Achieve programmable automatic biopsy system, Temno biopsy system, and Tru-Cut biopsy needles. This agreement is in connection with and subject to closing of BD’s proposed acquisition of C.R. Bard, Inc. and other customary closing conditions.

In addition, Merit proposes to acquire Bard’s Aspira pleural effusion drainage kits and Aspira peritoneal drainage system.

The current purchase price for these product lines and related assets is $100 million, advised the company in its announcement. 

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.